Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial - Ars Technica

As reported by Ars Technica

The interim Phase I trial data was only from 35 people, but results look good so far.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Ars Technica ↗

Market Samachar is a news aggregator. This article was originally published by Ars Technica. Tap the button above to read the full story on their site.

INDIAN Claude-maker Anthropic halves list of unauthorised share trading platforms after investor concerns: Which firms remain? mint - markets
CRYPTO SEC charges Texas man with $12.3M crypto fraud using fake AI trading bots Cointelegraph.com News
CRYPTO Florida Candidate Liquidates $800K in Bitcoin to Bankroll Congressional Bid Decrypt
GLOBAL DOJ seeks Judge Eleanor Ross recusal in Georgia election case, citing reports she was disciplined CNBC
GLOBAL Net worth matters more than income when it comes to financial anxiety, survey finds CNBC
GLOBAL IMF, World Bank, others warn Middle East war is straining energy supplies - Reuters Reuters
CRYPTO SEC sues Texas man over $12.3 million alleged crypto scheme built on fake AI trading bots CoinDesk: Bitcoin, Ethereum, Crypto News and Price Data
CRYPTO U.S. says it seized about $1 billion in Iranian crypto as pressure campaign expands CoinDesk: Bitcoin, Ethereum, Crypto News and Price Data

Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial - Ars Technica

More from Market Samachar